CALL: 1-855-344-3298 | AUSTIN | CORPUS CHRISTI | BOSTON
Hit enter to search or ESC to close
Hilliard Shadowen LLPHilliard Shadowen LLP
  • HOME
  • ABOUT
  • PRACTICE AREAS
    • ANTITRUST
    • CIVIL RIGHTS
  • NEWS
  • RESOURCES
  • CONTACT

CALL: 1-855-344-3298 | AUSTIN | CORPUS CHRISTI | BOSTON

  • HOME
  • ABOUT
  • PRACTICE AREAS
    • ANTITRUST
    • CIVIL RIGHTS
  • NEWS
  • RESOURCES
  • CONTACT
Category

Antitrust

Antitrust

Pharma Giants’ $454M Glumetza Antitrust Deal Gets Initial OK

Antitrust

Lupin agrees to pay $150 mln to settle Glumetza antitrust claims

Antitrust

Bausch to pay $300 mln in antitrust suit over diabetes drug

Antitrust

Takeda Can’t Duck Generic-Drug Delay Suit at 2nd Circ.

Antitrust

Bausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza

Antitrust

2nd Circ. Questions Takeda’s ‘Lazarus’ Take On Drug Patents

Antitrust

Glumetza Buyers Get Cert. In Suit Over 800% Price Jump

Antitrust

Gilead Can’t Fend Off Antitrust Suit Over HIV Drug Pricing (3)

Antitrust

HIV Drug Suit Against Gilead, BMS And Janssen Trimmed

Antitrust

IMPAX CAN’T USE ‘UNRELATED BENEFITS,’ AGS TELL 5TH CIRC.

1 2 Next

Recent Posts

  • U.S. States, Cities, and Experts Back Mexico’s Lawsuit Against Gunmakers
  • Pharma Giants’ $454M Glumetza Antitrust Deal Gets Initial OK
  • Lupin agrees to pay $150 mln to settle Glumetza antitrust claims
  • Bausch to pay $300 mln in antitrust suit over diabetes drug
  • Mexico is suing US gunmakers for thousands of guns trafficked across the border each year. Can they win?

Recent Comments

    © 2020 Hilliard Shadowen | All Rights Reserved | Designed by Media Digital Source

    Media Digital Source